Search

Your search keyword '"Jeffrey S. Humphrey"' showing total 21 results

Search Constraints

Start Over You searched for: Author "Jeffrey S. Humphrey" Remove constraint Author: "Jeffrey S. Humphrey"
21 results on '"Jeffrey S. Humphrey"'

Search Results

1. Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia

2. MPN-343: The BET Inhibitor Pelabresib Decreases Inflammatory Cytokines, Improves Bone Marrow Fibrosis and Function, and Demonstrates Clinical Response Irrespective of Mutation Status in Myelofibrosis Patients in the Phase 2 MANIFEST Trial

3. MPN-336: MANIFEST-2, a Global, Phase 3, Randomized, Double-Blind, Active-Control Study of CPI-0610 and Ruxolitinib vs Placebo and Ruxolitinib in JAKi Treatment-Naïve Myelofibrosis Patients

4. The BET Inhibitor, CPI-0610, Promotes Myeloid Differentiation in Myelofibrosis Patient Bone Marrow and Peripheral CD34+ Hematopoietic Stem Cells

5. MANIFEST-2, a Global, Phase 3, Randomized, Double-Blind, Active-Control Study of CPI-0610 and Ruxolitinib Vs. Placebo and Ruxolitinib in JAK-Inhibitor-Naive Myelofibrosis Patients

6. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

7. A Phase I Study of Oral BMS-275291, a Novel Nonhydroxamate Sheddase-Sparing Matrix Metalloproteinase Inhibitor, in Patients with Advanced or Metastatic Cancer

9. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene

10. Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density

11. Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations

12. The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee

13. Yeast-based assays for detection and characterization of mutations in BRCA1

14. Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancer

16. Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor

17. Acute renal toxicity associated with suramin in the treatment of prostate cancer

18. Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma

19. Von Hippel-Lindau syndrome: hereditary cancer arising from inherited mutations of the VHL tumor suppressor gene

20. Measuring the cost-effectiveness (CE) of therapies treating metastatic colorectal cancer (mCRC)

21. Value of Survival Gains In Chronic Myelogenous Leukemia

Catalog

Books, media, physical & digital resources